
Opinion|Videos|May 23, 2025
The Future of Chronic Hand Eczema Treatment
Author(s)Raj Chovatiya, MD, PhD
An expert discusses how new treatments for chronic hand eczema (CHE) are emerging, particularly topical delgocitinib cream, a pan-Janus kinase (JAK) inhibitor that shows promise for treating multiple etiologies of the condition without the limitations of traditional topical steroids.
Advertisement
Video content above is prompted by the following:
Future Directions of CHE Treatment
Key Themes:
- Emerging therapies: Topical delgocitinib cream, a pan-JAK inhibitor, shows promise specifically for CHE.
- Other investigational options: Topical ruxolitinib, dupilumab, and tralokinumab have shown efficacy in certain CHE populations.
- Clinical approach: Avoiding treatment delays while pursuing diagnostic workup, with consideration for targeted therapies across multiple etiologies.
Notable Insights:
Dr Chovatiya emphasized that "having a cream that can help patients across etiologies and not delay their actual treatment represents a huge potential win for us in dermatology," suggesting a paradigm shift in CHE management.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on HCPLive
1
SimpleScreen CRC Blood Test Meets Endpoints in Clinical Validation Study
2
Liver Lineup: Bepirovirsen and the Push Toward Functional Cure in Hepatitis B
3
Eplontersen Misses Primary Endpoint in Phase 3 ATTR-CM Trial
4
Biologic Therapy for Asthma and COPD: Real-World Perspectives From APPs
5
















































































